Top in rheumatology: Sotrovimab for COVID-19, Xeljanz for ankylosing spondylitis

109260

Sumary of Top in rheumatology: Sotrovimab for COVID-19, Xeljanz for ankylosing spondylitis:

  • Another top story shared study data on tofacitinib (Pfizer) as a treatment for adults with ankylosing spondylitis..
  • The FDA’s authorization of sotrovimab to treat mild-to-moderate COVID-19 in patients aged older than 12 years was the top story in rheumatology last week..
  • The FDA has issued an emergency use authorization for the monoclonal antibody sotrovimab sotrovimab (VIR-7831, GlaxoSmithKline) to treat mild-to-moderate COVID-19 in patients at risk for progressing to severe disease, according to a press release..
  • Erosive hand osteoarthritis tends to target older adults and women with preexisting OA, and is associated with severe articular structural damage and radiographic progression, according to data published in Arthritis &…

Want to know more click here go to source.

From -
Close
Generic selectors
Exact matches only
Search in title
Search in content

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close